Repligen Corporation to Present at Upcoming May Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will attend several investor conferences in May, including RBC Capital Markets' Global Healthcare Conference in New York, Craig-Hallum's Institutional Investor Conference in Minneapolis, and Leerink Partners' Healthcare Crossroads Conference in Austin. Jason K. Garland, Chief Financial Officer, will participate in analyst-led discussions and one-on-one meetings with investors at each event. Live webcasts of the RBC and Leerink presentations will be accessible via Repligen's Investor Relations website.
Details
News Market Reaction – RGEN
The recorded move for RGEN in the trading session of this news was -0.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
- RBC Capital Markets’ 2024 Global Healthcare Conference, being held in New York on May 14-15. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 14, 2024 at 10:30 a.m. ET, in addition to a series of one-on-one meetings with investors.
- Craig-Hallum’s 21st Annual Institutional Investor Conference, being held in Minneapolis on May 29. Jason K. Garland, Chief Financial officer will participate in a series of one-on-one meetings with investors.
- Leerink Partners’ 2024 Healthcare Crossroads Conference, being held in Austin, Texas on May 28-29. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 30, 2024 at 8:40 a.m. CT, in addition to a series of one-on-one meetings with investors.
A live webcast of the RBC and Leerink conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.